|
|
| | SB242235 Basic information |
| Product Name: | SB242235 | | Synonyms: | SB242235;4-[4-(4-Fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl]-2-methoxypyrimidine;4-(4-(4-Fluorophenyl)-1-(piperidin-4-yl)-1H-iMidazol-5-yl)-2-MethoxypyriMidine;SB-242235; SB242235;CS-668;SB242235 ≥95%;Pyrimidine, 4-[4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl]-2-methoxy-;inhibit,SB 242235,Autophagy,Inhibitor,p38 MAPK | | CAS: | 193746-75-7 | | MF: | C19H20FN5O | | MW: | 353.39 | | EINECS: | | | Product Categories: | | | Mol File: | 193746-75-7.mol |  |
| | SB242235 Chemical Properties |
| Boiling point | 568.4±60.0 °C(Predicted) | | density | 1.34 | | storage temp. | 2-8°C(protect from light) | | solubility | DMF: 25 mg/ml; DMSO: 20 mg/ml; Ethanol: 30 mg/ml | | form | Powder | | pka | 9.91±0.10(Predicted) |
| | SB242235 Usage And Synthesis |
| Biological Activity | SB-242235 is a potent and selective p38 MAP kinase inhibitor with IC50 of 1.0 μM in human chondrocytes. | | in vitro | SB 242235 (0-10 μM) dose-dependently inhibits the activation of MAPKAP K2 with an IC 50 of 1.0 μM in human chondrocytes stimulated with IL-1β.
SB 242235 inhibits intracellular p38 activity, MAPKAP K2 was then isolated from these cells and assayed using HSP27 as a substrate.
Western Blot Analysis | Cell Line: | Human chondrocytes | | Concentration: | 0 μM, 0.01 μM, 0.1 μM, 1 μM, 10 μM | | Incubation Time: | < td class="col2"> 15 minutes | Result: | Dose-dependently inhibited the activation of MAPKAP K2 with an IC 50 of 1.0 μM. | | | target | IC50: 1.0 μM (p38 MAPK, primary human chondrocytes) |
| | SB242235 Preparation Products And Raw materials |
|